Pidotimod (Polimod ®) is a synthetic dipeptide molecule with biological and immunological activity on both the adaptive and the innate immune responses. In vitro studies, both from animal and human specimens, have documented a good activity on innate and adaptive immune responses and have been confirmed by in vivo studies. These activities have been applied in clinical studies demonstrating the efficacy of pidotimod in reducing the rate of recurrent infections of the upper respiratory and urinary tracts in children. The same results were obtained in recurrent respiratory tract infections in adults. Interestingly, these effects are more evident in the setting of immune defects such as senescence, Down's syndrome, and cancer.
CoppiGFalconeAManzardoS. Protective effects of pidotimod against experimental bacterial infections in mice. Arzneim Forsch Drug Res1994; 44:1417–21.
2.
DianzaniCColangeloDTonsoEGuidottoSVianoI. In vivo antiviral effects of pidotimod. Arzneim Forsch Drug Res1994; 44:1431–3.
3.
MarelliPLupettiASenesiSUslenghiCGirardelloRCampaM., Potenziamento della resistenza alle infezioni virali e batteriche dopo somministrazione di pidotimod nel topo. Drugs Exp Clin Res1993; XIX: 15–21.
4.
TaramelliDMalabarbaMGBasiliscoNSalaGMattinaRCocuzzaC. Effects of pidotimod on macrophage functions in methylprednisolone-treated mice. Arzneim Forsch Drag Res1994; 44:1425–30.
5.
MiglioratiGNicolettiIRiccardiG. Immunomodulating activity of pidotimodArzneim Forsch Drug Res1994; 44:1421–4.
6.
CoppiGManzanardoS. Experimental immunological screening test on pidotimod. Arzneim Forsch Drug Res1994; 44:1411–6.
7.
ChiarenzaAIuratoMPBarberaNLempereurLCantarellaGScapagniniUBernardiniR. Modulating effects of the synthetic thymic dipeptide pidotimod on the immune system in the aging rat. Pharmacology and Toxicology1994; 74:262–6.
8.
ChiarenzaAIuratoMPBarberaNLempereurLCantarellaGScapagniniUScapagniniGBernardiniR. Effects of pidotimod on the immune and the neuroendocrine system in the aging rat. Arzneim Forsch Drug Res1994; 44:1437–40.
9.
CapsoniFMinonzioFOngariAMGirardelloRDi BelloMZanussiC. In vitro and ex vivo enhancement of neutrophil functions by PGT/1A, a new immunostimulating peptide. J Chemother1991; 3:147–49.
10.
CaramiaGClementeESolliRMeiVCeraRCarnelliVVenturosiVCorsiniA. Efficacy and safety of pidotimod in the treatment of recurrent respiratory infections in children. Arzneim Forsch1994; 44:1480–4.
11.
OdderaSSilvestriMSaccoOEftimiadiCRossiG. Effetto del pidotimod sulla fagocitosi e sul killing intracellulare di Staphylococcus aureus da parte di polimorfonucleati neutrofili circolanti e di macrofagi alveolari umani. Drugs Exp Clin Res1993; XIX:27–35.
12.
IlleniMTBombelliGPattarinoPLPoliA. NK cell cytotoxic activity induced by a synthetic immunostimulant (pidotimod): An in vitro study. J Chemother1991; 3:157–9.
13.
PuglieseAUslenghiCTorreDD'AlonzoLCorgnatiFGirardelloR. Evaluation of the effect of pidotimod on the in vitro production of interferons. Int J Immunotherapy1995; 11:71–6.
14.
Di RenzoMPasquiALBroniF. The in vitro effect of pidotimod on some immune function in cancer patients. Immunopharm Immunot1997; 19:37–51.
15.
BenettiGPFugazzaLBadialeM StrambaMontaltoF. Bombelli G, La Vecchia G, Illeni MT, Uslenghi C. Ex vivo evaluation of pidotimod activity on cell-mediated immunity. Arzneim Forsch Drug Res1994; 44:1476–9.
16.
AwDSilvaABPalmerDB. Immunosenescence: Emerging challenger for an aging population. Immunology2007; 120:435–46.
17.
BorghiMOFainCBarcelliniWDel PapaNLa RosaLNicolettiFUslenghiCMeroniPL. Ex vivo effect of pidotimod on peripheral blood mononuclear cell immune functions: Study of an elderly population. Int J Immunotherapy1994; 10: 35–9.
18.
BurgioGRMarsegliaGLSeveriFMasaroneMOttolenghiAPaglianoLSerraVNespoliL. Immunoactivation by pidotimod in children with recurrent respiratory infections. Arzneim Forsch Drug Res1994; 44:1525–9.
19.
CaredduP. Role of immunoactivation with pidotimod in recurrent respiratory infections in childhood. Arzneim Forsch Drug Res1994; 44:1506–11.
20.
CaredduPMeiVVenturosiVCorsiniA. Pidotimod in the treatment of recurrent respiratory infections in paediatric patients. Arzneim Forsch Drug Res1994; 44:1485–9.
21.
ClementeESolliRMeiVCeraRCaramiaGCarnelliVRuffiniEVenturosiVCorsiniA. Therapeutic efficacy and safety of pidotimod in the treatment of urinary tract infections in children. Arzneim Forsch Drug Res1994; 44:1490–4.
22.
AivasisVHatzimichailAPapachristouAValeriRIuga-DoncaG. Clinical evaluation and changes of the respiratory epithelium function after administration of pidotimod in Greek children with recurrent respiratory tract infections. Minerva Pediatr2002; 54:345–9.
23.
CaredduPAlfanoSZavattiniG. Pidotimod in the prophylaxis of recurrent acute tonsillitis in childhood. Adv Ther1992; 9:174–83.
24.
PozziEDolcettiAOrlandiOCirianniCMoreoGPiacenzaGRampollaCScarpazzaG. Pidotimod in the treatment of patients affected by bacterial exacerbations of chronic bronchitis. Arzneim Forsch Drug Res1994; 44:1495–8.
25.
BisettiACiappiGBariffiF. Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronchitisArzneim Forsch Drug Res1994; 44:1499–502.
26.
Ciaccia A and a multicenter study group. Pidotimod activity against chronic bronchitis exacerbation. Arzneim Forsch Drug Res1994; 44:1516–20.
27.
CogoRRamponiAMonzaniGUslenghiCGirardelloR. Valutazione dell'attività di pidotimod sulla secrezione di IgA in pazienti affetti da BPCO. Gior It Allergol Immuno Clin1993; 3:253–9.
28.
CorreaJB VargasMoralesS EspinosaAnconaJC BolanosAleJA Faràn. Pidotimod en infeccion respiratoria recurrente en el nino con rinitis alérgica, asma o ambos padecimientos. Revista Alergia Mexico2002; XLIX:27–30.
29.
AuteriAPasquiALGottiG. The effect of a new biological response modifier (pidotimod) on surgery-associated immunodeficiency. Int J Immunother1993; IX:95–102.
30.
AnnoniGPoliA. Studio policentrico controllato sulla attività immunostimolante di PGT/1A nel paziente anziano con patologia internistica e chirurgica. NAM1991; 7:45–52.
31.
CogoRFurcoloFMonzaniGP. Studio clinico sull'acido timodolico nel trattamento delle infezioni delle vie respiratorie. NAM1989; 5:492–7.
32.
La MantiaIGrilloCMattinaTZacconePXiangMDi MauroMMeroniPLNicolettiF. Prophylaxis with the novel immunomodulator pidotimod reduces the frequency and severity of upper respiratory tract infections in children with Down's syndromeJ Chemother1999; 11:126–30.
33.
GourgiotisDPapadopoulosNGBossiosAZamanisPSaxoni-PapageorgiouP. Immune modulator pidotimod decreases the in vitro expression of CD30 in peripheral blood mononuclear cells of atopic asthmatic and normal children. J Asthma2004; 41:285–7.
